HAEM5:Mantle cell lymphoma: Difference between revisions - Compendium of Cancer Genome Aberrations

Line 83:

<blockquote class='blockedit'>{{Box-round|title=v4:Clinical Features|The content below was from the old template. Please incorporate above.}}

<blockquote class='blockedit'>{{Box-round|title=v4:Clinical Features|The content below was from the old template. Please incorporate above.}}</blockquote>

Line 107:

<blockquote class='blockedit'>{{Box-round|title=Unassigned References|The following referenees were placed in the header. Please place them into the appropriate locations in the text.}}<ref>Arber, D.A., et al., ''Hematopathology''. 2017, Philadelphia, PA: Elsevier.</ref></blockquote>

<blockquote class='blockedit'>{{Box-round|title=Unassigned References|The following referenees were placed in the header. Please place them into the appropriate locations in the text.}}</blockquote><ref>Arber, D.A., et al., ''Hematopathology''. 2017, Philadelphia, PA: Elsevier.</ref><blockquote class="blockedit">

<center>'''End of V4 Section'''

----

<center>'''End of V4 Section'''

----

</blockquote>

==Sites of Involvement==

Line 263:

Line 269:

<blockquote class='blockedit'>{{Box-round|title=v4:Chromosomal Rearrangements (Gene Fusions)|The content below was from the old template. Please incorporate above.}}

<blockquote class='blockedit'>{{Box-round|title=v4:Chromosomal Rearrangements (Gene Fusions)|The content below was from the old template. Please incorporate above.}}</blockquote>

Line 293:

Line 299:

<blockquote class='blockedit'>{{Box-round|title=Unassigned References|The following referenees were placed in the header. Please place them into the appropriate locations in the text.}}<ref>{{Cite journal|last=Martín-Garcia|first=David|last2=Navarro|first2=Alba|last3=Valdés-Mas|first3=Rafael|last4=Clot|first4=Guillem|last5=Gutiérrez-Abril|first5=Jesús|last6=Prieto|first6=Miriam|last7=Ribera-Cortada|first7=Inmaculada|last8=Woroniecka|first8=Renata|last9=Rymkiewicz|first9=Grzegorz|date=02 28, 2019|title=CCND2 and CCND3 hijack immunoglobulin light-chain enhancers in cyclin D1- mantle cell lymphoma|url=https://pubmed.ncbi.nlm.nih.gov/30538135|journal=Blood|volume=133|issue=9|pages=940–951|doi=10.1182/blood-2018-07-862151|issn=1528-0020|pmc=6396173|pmid=30538135}}</ref></blockquote>

<blockquote class='blockedit'>{{Box-round|title=Unassigned References|The following referenees were placed in the header. Please place them into the appropriate locations in the text.}}</blockquote><ref>{{Cite journal|last=Martín-Garcia|first=David|last2=Navarro|first2=Alba|last3=Valdés-Mas|first3=Rafael|last4=Clot|first4=Guillem|last5=Gutiérrez-Abril|first5=Jesús|last6=Prieto|first6=Miriam|last7=Ribera-Cortada|first7=Inmaculada|last8=Woroniecka|first8=Renata|last9=Rymkiewicz|first9=Grzegorz|date=02 28, 2019|title=CCND2 and CCND3 hijack immunoglobulin light-chain enhancers in cyclin D1- mantle cell lymphoma|url=https://pubmed.ncbi.nlm.nih.gov/30538135|journal=Blood|volume=133|issue=9|pages=940–951|doi=10.1182/blood-2018-07-862151|issn=1528-0020|pmc=6396173|pmid=30538135}}</ref><blockquote class="blockedit">

<center>'''End of V4 Section'''

----

<center>'''End of V4 Section'''

----

</blockquote>

Line 301:

Line 313:

* Individual Region Genomic Gain/Loss/LOH

* Characteristic Chromosomal Patterns

* Gene Mutations (SNV/INDEL)}}

* Gene Mutations (SNV/INDEL)}}</blockquote>

* Median survival: 5 - 7 years

Line 325:

Line 337:

*** High-risk patients based on MIPI-C

<center>'''End of V4 Section'''

----

</blockquote>

==Individual Region Genomic Gain / Loss / LOH==

Line 373:

Line 388:

|}

<blockquote class='blockedit'>{{Box-round|title=v4:Genomic Gain/Loss/LOH|The content below was from the old template. Please incorporate above.}}

<blockquote class='blockedit'>{{Box-round|title=v4:Genomic Gain/Loss/LOH|The content below was from the old template. Please incorporate above.}}</blockquote>

Secondary chromosomal aberrations<ref>{{Cite journal|last=C|first=Royo|last2=I|first2=Salaverria|last3=Em|first3=Hartmann|last4=A|first4=Rosenwald|last5=E|first5=Campo|last6=S|first6=Beà|date=2011|title=The complex landscape of genetic alterations in mantle cell lymphoma|url=https://pubmed.ncbi.nlm.nih.gov/21945515/|language=en|pmid=21945515}}</ref>

Line 535:

Line 550:

|}

<center>'''End of V4 Section'''

----

</blockquote>

==Characteristic Chromosomal Patterns==

Line 559:

Line 577:

|}

<blockquote class='blockedit'>{{Box-round|title=v4:Characteristic Chromosomal Aberrations / Patterns|The content below was from the old template. Please incorporate above.}}

<blockquote class='blockedit'>{{Box-round|title=v4:Characteristic Chromosomal Aberrations / Patterns|The content below was from the old template. Please incorporate above.}}</blockquote>

*''CCND1'' rearrangement; t(11;14)(q13;q32)

Line 604:

Line 622:

|}

<center>'''End of V4 Section'''

----

</blockquote>

==Gene Mutations (SNV / INDEL)==

Line 639:

Line 660:

<blockquote class='blockedit'>{{Box-round|title=v4:Gene Mutations (SNV/INDEL)|The content below was from the old template. Please incorporate above.}}

<blockquote class='blockedit'>{{Box-round|title=v4:Gene Mutations (SNV/INDEL)|The content below was from the old template. Please incorporate above.}}</blockquote>

Line 763:

Line 784:

<blockquote class='blockedit'>{{Box-round|title=Unassigned References|The following referenees were placed in the header. Please place them into the appropriate locations in the text.}}<ref>{{Cite journal|last=Rosenquist|first=R.|last2=Beà|first2=S.|last3=Du|first3=M.-Q.|last4=Nadel|first4=B.|last5=Pan-Hammarström|first5=Q.|date=11 2017|title=Genetic landscape and deregulated pathways in B-cell lymphoid malignancies|url=https://pubmed.ncbi.nlm.nih.gov/28631441|journal=Journal of Internal Medicine|volume=282|issue=5|pages=371–394|doi=10.1111/joim.12633|issn=1365-2796|pmid=28631441}}</ref></blockquote>

<blockquote class='blockedit'>{{Box-round|title=Unassigned References|The following referenees were placed in the header. Please place them into the appropriate locations in the text.}}</blockquote><ref>{{Cite journal|last=Rosenquist|first=R.|last2=Beà|first2=S.|last3=Du|first3=M.-Q.|last4=Nadel|first4=B.|last5=Pan-Hammarström|first5=Q.|date=11 2017|title=Genetic landscape and deregulated pathways in B-cell lymphoid malignancies|url=https://pubmed.ncbi.nlm.nih.gov/28631441|journal=Journal of Internal Medicine|volume=282|issue=5|pages=371–394|doi=10.1111/joim.12633|issn=1365-2796|pmid=28631441}}</ref><blockquote class="blockedit">

<center>'''End of V4 Section'''

----

<center>'''End of V4 Section'''

----

</blockquote>

==Epigenomic Alterations==

Line 789:

Line 816:

|}

<blockquote class='blockedit'>{{Box-round|title=v4:Genes and Main Pathways Involved|The content below was from the old template. Please incorporate above.}}

<blockquote class='blockedit'>{{Box-round|title=v4:Genes and Main Pathways Involved|The content below was from the old template. Please incorporate above.}}</blockquote>

Please refer to Gene Mutations (SNV/INDEL)

<center>'''End of V4 Section'''

----

</blockquote>

==Genetic Diagnostic Testing Methods==

@@ Line 83: / Line 83: @@
-<blockquote class='blockedit'>{{Box-round|title=v4:Clinical Features|The content below was from the old template. Please incorporate above.}}
+<blockquote class='blockedit'>{{Box-round|title=v4:Clinical Features|The content below was from the old template. Please incorporate above.}}</blockquote>
@@ Line 107: / Line 107: @@
-<blockquote class='blockedit'>{{Box-round|title=Unassigned References|The following referenees were placed in the header. Please place them into the appropriate locations in the text.}}<ref>Arber, D.A., et al., ''Hematopathology''. 2017, Philadelphia, PA: Elsevier.</ref></blockquote>
+<blockquote class='blockedit'>{{Box-round|title=Unassigned References|The following referenees were placed in the header. Please place them into the appropriate locations in the text.}}</blockquote><ref>Arber, D.A., et al., ''Hematopathology''. 2017, Philadelphia, PA: Elsevier.</ref><blockquote class="blockedit">
+<center><span style="color:Maroon">'''End of V4 Section'''</span>
+----
+<blockquote class="blockedit">
+<center><span style="color:Maroon">'''End of V4 Section'''</span>
+----
+</blockquote>
 </blockquote>
 ==Sites of Involvement==
@@ Line 263: / Line 269: @@
-<blockquote class='blockedit'>{{Box-round|title=v4:Chromosomal Rearrangements (Gene Fusions)|The content below was from the old template. Please incorporate above.}}
+<blockquote class='blockedit'>{{Box-round|title=v4:Chromosomal Rearrangements (Gene Fusions)|The content below was from the old template. Please incorporate above.}}</blockquote>
@@ Line 293: / Line 299: @@
-<blockquote class='blockedit'>{{Box-round|title=Unassigned References|The following referenees were placed in the header. Please place them into the appropriate locations in the text.}}<ref>{{Cite journal|last=Martín-Garcia|first=David|last2=Navarro|first2=Alba|last3=Valdés-Mas|first3=Rafael|last4=Clot|first4=Guillem|last5=Gutiérrez-Abril|first5=Jesús|last6=Prieto|first6=Miriam|last7=Ribera-Cortada|first7=Inmaculada|last8=Woroniecka|first8=Renata|last9=Rymkiewicz|first9=Grzegorz|date=02 28, 2019|title=CCND2 and CCND3 hijack immunoglobulin light-chain enhancers in cyclin D1- mantle cell lymphoma|url=https://pubmed.ncbi.nlm.nih.gov/30538135|journal=Blood|volume=133|issue=9|pages=940–951|doi=10.1182/blood-2018-07-862151|issn=1528-0020|pmc=6396173|pmid=30538135}}</ref></blockquote>
+<blockquote class='blockedit'>{{Box-round|title=Unassigned References|The following referenees were placed in the header. Please place them into the appropriate locations in the text.}}</blockquote><ref>{{Cite journal|last=Martín-Garcia|first=David|last2=Navarro|first2=Alba|last3=Valdés-Mas|first3=Rafael|last4=Clot|first4=Guillem|last5=Gutiérrez-Abril|first5=Jesús|last6=Prieto|first6=Miriam|last7=Ribera-Cortada|first7=Inmaculada|last8=Woroniecka|first8=Renata|last9=Rymkiewicz|first9=Grzegorz|date=02 28, 2019|title=CCND2 and CCND3 hijack immunoglobulin light-chain enhancers in cyclin D1- mantle cell lymphoma|url=https://pubmed.ncbi.nlm.nih.gov/30538135|journal=Blood|volume=133|issue=9|pages=940–951|doi=10.1182/blood-2018-07-862151|issn=1528-0020|pmc=6396173|pmid=30538135}}</ref><blockquote class="blockedit">
+<center><span style="color:Maroon">'''End of V4 Section'''</span>
+----
+<blockquote class="blockedit">
+<center><span style="color:Maroon">'''End of V4 Section'''</span>
+----
+</blockquote>
 </blockquote>
@@ Line 301: / Line 313: @@
 * Individual Region Genomic Gain/Loss/LOH
 * Characteristic Chromosomal Patterns
-* Gene Mutations (SNV/INDEL)}}
+* Gene Mutations (SNV/INDEL)}}</blockquote>
 * Median survival: 5 - 7 years
@@ Line 325: / Line 337: @@
 *** High-risk patients based on MIPI-C
+<blockquote class="blockedit">
+<center><span style="color:Maroon">'''End of V4 Section'''</span>
+----
 </blockquote>
 ==Individual Region Genomic Gain / Loss / LOH==
@@ Line 373: / Line 388: @@
 |}
-<blockquote class='blockedit'>{{Box-round|title=v4:Genomic Gain/Loss/LOH|The content below was from the old template. Please incorporate above.}}
+<blockquote class='blockedit'>{{Box-round|title=v4:Genomic Gain/Loss/LOH|The content below was from the old template. Please incorporate above.}}</blockquote>
 Secondary chromosomal aberrations<ref>{{Cite journal|last=C|first=Royo|last2=I|first2=Salaverria|last3=Em|first3=Hartmann|last4=A|first4=Rosenwald|last5=E|first5=Campo|last6=S|first6=Beà|date=2011|title=The complex landscape of genetic alterations in mantle cell lymphoma|url=https://pubmed.ncbi.nlm.nih.gov/21945515/|language=en|pmid=21945515}}</ref>
@@ Line 535: / Line 550: @@
 |}
+<blockquote class="blockedit">
+<center><span style="color:Maroon">'''End of V4 Section'''</span>
+----
 </blockquote>
 ==Characteristic Chromosomal Patterns==
@@ Line 559: / Line 577: @@
 |}
-<blockquote class='blockedit'>{{Box-round|title=v4:Characteristic Chromosomal Aberrations / Patterns|The content below was from the old template. Please incorporate above.}}
+<blockquote class='blockedit'>{{Box-round|title=v4:Characteristic Chromosomal Aberrations / Patterns|The content below was from the old template. Please incorporate above.}}</blockquote>
 *''CCND1'' rearrangement; t(11;14)(q13;q32)
@@ Line 604: / Line 622: @@
 |}
+<blockquote class="blockedit">
+<center><span style="color:Maroon">'''End of V4 Section'''</span>
+----
 </blockquote>
 ==Gene Mutations (SNV / INDEL)==
@@ Line 639: / Line 660: @@
-<blockquote class='blockedit'>{{Box-round|title=v4:Gene Mutations (SNV/INDEL)|The content below was from the old template. Please incorporate above.}}
+<blockquote class='blockedit'>{{Box-round|title=v4:Gene Mutations (SNV/INDEL)|The content below was from the old template. Please incorporate above.}}</blockquote>
@@ Line 763: / Line 784: @@
-<blockquote class='blockedit'>{{Box-round|title=Unassigned References|The following referenees were placed in the header. Please place them into the appropriate locations in the text.}}<ref>{{Cite journal|last=Rosenquist|first=R.|last2=Beà|first2=S.|last3=Du|first3=M.-Q.|last4=Nadel|first4=B.|last5=Pan-Hammarström|first5=Q.|date=11 2017|title=Genetic landscape and deregulated pathways in B-cell lymphoid malignancies|url=https://pubmed.ncbi.nlm.nih.gov/28631441|journal=Journal of Internal Medicine|volume=282|issue=5|pages=371–394|doi=10.1111/joim.12633|issn=1365-2796|pmid=28631441}}</ref></blockquote>
+<blockquote class='blockedit'>{{Box-round|title=Unassigned References|The following referenees were placed in the header. Please place them into the appropriate locations in the text.}}</blockquote><ref>{{Cite journal|last=Rosenquist|first=R.|last2=Beà|first2=S.|last3=Du|first3=M.-Q.|last4=Nadel|first4=B.|last5=Pan-Hammarström|first5=Q.|date=11 2017|title=Genetic landscape and deregulated pathways in B-cell lymphoid malignancies|url=https://pubmed.ncbi.nlm.nih.gov/28631441|journal=Journal of Internal Medicine|volume=282|issue=5|pages=371–394|doi=10.1111/joim.12633|issn=1365-2796|pmid=28631441}}</ref><blockquote class="blockedit">
+<center><span style="color:Maroon">'''End of V4 Section'''</span>
+----
+<blockquote class="blockedit">
+<center><span style="color:Maroon">'''End of V4 Section'''</span>
+----
+</blockquote>
 </blockquote>
 ==Epigenomic Alterations==
@@ Line 789: / Line 816: @@
 |}
-<blockquote class='blockedit'>{{Box-round|title=v4:Genes and Main Pathways Involved|The content below was from the old template. Please incorporate above.}}
+<blockquote class='blockedit'>{{Box-round|title=v4:Genes and Main Pathways Involved|The content below was from the old template. Please incorporate above.}}</blockquote>
 Please refer to Gene Mutations (SNV/INDEL)
+<blockquote class="blockedit">
+<center><span style="color:Maroon">'''End of V4 Section'''</span>
+----
 </blockquote>
 ==Genetic Diagnostic Testing Methods==